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Abstract
Background: The rapidly expanding arsenal of chemotherapeutic agents approved in the past 5 years represents
significant progress in the field. However, this poses a challenge for oncologists to choose which drug or
combination of drugs is best for any individual. Because only a fraction of patients respond to any drug, efforts
have been made to devise strategies to personalize care. The majority of efforts have involved development of
predictive biomarkers. While there are notable successes, there are no predictive biomarkers for most drugs.
Moreover, predictive biomarkers enrich the cohort of individuals likely to benefit; they do not guarantee benefit.
Main text: There is a need to devise alternate strategies to tailor cancer care. One alternative approach is to
enhance the current adaptive approach, which involves administration of a drug and cessation of treatment once
progression is documented. This currently involves radiographic tests for the most part, which are expensive,
inconvenient and imperfect in their ability to categorize patients who are and are not benefiting from treatment. A
biomarker approach to categorizing response may have advantages.
Conclusion: Herein, we discuss the state of the art on treatment response assessment. While the most mature
technologies for response assessment involve radiographic tests such as CT and PET, reports are emerging on
biomarkers used to monitor therapeutic efficacy. Potentially, response biomarkers represent a less expensive and
more convenient means of monitoring therapy, although an ideal response biomarker has not yet been described.
A framework for future response biomarker discovery is described.
Keywords: Response Biomarker, Predictive biomarker, RECIST, Assessing response, Adaptive biomarker, Systemic
therapy, Cancer
Background
For many solid tumors, the therapeutic armamentarium is
rapidly expanding, particularly with advances in
molecularly-targeted drugs. But only a fraction of patients
are responsive to any antineoplastic drug, and there is a
need to better tailor therapy for any individual. The
present approach to the palliative management of solid tu-
mors involves administering a drug (or combination of
drugs) that the oncologist speculates will be effective in a
given tumor type. Following a significant exposure to
chemotherapy (typically over several months), the oncolo-
gist estimates response radiographically. However, the
radiographic features of a response to chemotherapy are
not always obvious. Moreover, if disease progression oc-
curs while on chemotherapy, the patient has had to suffer
any toxicities related to the drugs; and the patient’s condi-
tion may have deteriorated (due to disease progression, as
well as toxicities). This could interfere with administration
of subsequent lines of chemotherapy. Meanwhile, the
payer is saddled with the costs of an ineffective therapy.
There is little argument that oncologic care must be
personalized. Biomarkers represent one strategy to tailor
therapy. However, the vast majority of our efforts have
focused on development of prognostic and predictive
biomarkers, which has had limited success. Response
biomarkers have not been thoroughly explored. The pur-
pose of this review is to discuss the potential advantages
of response biomarkers, and to envisage how a better
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response biomarker might transform clinical practice as
well as drug development.
Increasing complexity of the therapeutic landscape: the
impending crisis
In recent decades, chemotherapeutic agents used in clin-
ical practice consisted mainly of cytotoxic drugs. The
stochastic increase in response rates in some tumor
types resulted mostly from drugs used in combination,
at the cost of some increase in toxicity. More recently,
there has been a rapid proliferation of agents that specif-
ically target an ever expanding array of molecules. In
general, these molecularly targeted agents are cytostatic,
making it more difficult to assess their contribution to
the health of the patient.
The rate of FDA drug approval for treatment of can-
cers has been accelerating (Fig. 1a). Therefore, for the
practicing oncologist, the choice of which agent (s) to
administer to any individual is becoming more complex.
At the same time, oncologists are limited to drugs ap-
proved by their formulary. Cost and evidence of effect-
iveness from large clinical trials affect the availability of
drugs in the formulary, perhaps restricting access to po-
tentially effective drugs in an individual.
The drug development pipeline is sizeable. As of the time
of this writing, it is estimated that 320 drugs are in phase I
and II stages of development [1]. Given the finite patient re-
sources and financial constraints of industry and clinical
trial groups, only a small proportion of these drugs will ever
reach phase III trials (Fig. 1b). The cost of developing a
drug is estimated to be a staggering $1.3 billion [2]. Even
those drugs tested in phase III trials may never be adopted
into clinical practice because they do not increase survival
in the aggregate patient population, or because the magni-
tude of their benefit to the aggregate is insufficient to war-
rant the costs. This bottleneck has some important
implications. First, a number of potentially useful drugs
may remain untested in phase III trials because so many
drugs with a positive phase II signal are competing for in-
clusion in larger trials. Second, drugs that are useful to indi-
viduals may not be approved because of insufficient effect
on the study population as a whole.
Clearly, a more efficient approach is required to de-
velop and test drugs, to determine which drug (s) benefit
an individual, and to ensure that drugs that benefit indi-
viduals (but perhaps not the aggregate) are available.
The problem with predictive biomarkers
Most systemic agents or drug combinations used for
solid tumors only benefit a fraction of individuals. This
is readily observable whenever progression-free survival
(PFS) is illustrated for any drug trial. Therefore, given
the toxicity of these agents as well as their cost, there is
a need to identify individuals who will benefit. Presently,
the dominant approach to personalizing therapy involves









































Success Rate for Progression
to Next Level of Development
NDA to Approval: 77%-93%
Phase 3 to NDA: 42%-60%
Phase 2 to 3: 16%-27%
Phase 1 to 2: 10.4%-19%
a
b
Fig. 1 The drug development pipeline for cancer. a Number of drugs approved each year by the FDA for the treatment of cancer, since 1999.
Figure is derived from the annual briefs on New Molecular Entity and New biologic Approvals [74]. b Probability of success in advancing a
proposed therapeutic compound from phase 1 clinical trials to FDA approval. Data are derived from Hay et al. [75]
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predictive biomarkers have entered clinical practice (in-
cluding KRAS mutation status, Her-2 expression, and
estrogen receptor expression), development of predictive
biomarkers is associated with a number of challenges.
Most importantly, predictive biomarkers are typically
specific to a particular agent; they reflect the presence of
the molecular derangements necessary for any drug to
exert its biological effect and the absence of mechanisms
of drug resistance. Therefore, for any new drug that be-
comes available, new avenues of research must be devel-
oped to identify and validate predictive biomarkers for
that new drug. As chemotherapeutic options become
more numerous, diagnostic laboratories will require
competence in more assays. The whole process of devel-
oping predictive biomarkers is therefore expensive and
time consuming.
Predictive biomarkers also do not guarantee benefit.
Rather, they are helpful in excluding patients from get-
ting a drug that will not benefit. This is illustrated in the
case of epidermal growth factor receptor (EGFR) in
colorectal cancer. A KRAS mutation predicts that an
EGFR inhibitor will not be beneficial; only about 1 % re-
spond to cetuximab. On the other hand, only 12.8 % of
individuals with KRAS wildtype have a measurable re-
sponse, and less than 60 % have a longer progression
free survival (PFS) than the median survival of patients
treated with best supportive care [3]. Similarly, the ab-
sence of estrogen receptor (ER) in breast cancer indi-
cates resistance to hormonal therapy, but only 50–75 %
of ER positive tumors respond to various hormone ma-
nipulations [4, 5]. Predictive markers are therefore far
from predictive.
Finally, there is the problem of defining a predictive
biomarker. Predictive biomarkers are defined and vali-
dated in randomized controlled trials in which a treat-
ment is not administered to a control group. In the
absence of a non-treatment group, it is difficult to dis-
criminate whether a biomarker that categorizes patient
survival is predictive or prognostic (reflecting biological
subsets). Prognostic biomarkers do not aid in making
go/no-go treatment decisions.
Response as an endpoint for drug development and
approval
Generally, for a cancer drug to be approved and intro-
duced to clinical practice, it must have an impact on sur-
vival. However, an aggregate survival benefit may be too
stringent a criterion, particularly in the advent of tar-
geted therapy, where ever-smaller chemosensitive sub-
groups have not been fully defined. Drugs that benefit
only the few will not measurably impact aggregate sur-
vival unless there is some way to enrich a study cohort
with chemosensitive participants.
There have been exceptions where drugs have been ap-
proved without demonstrable survival benefit. One ex-
ample is the approval of gemcitabine for unresectable
pancreatic cancer, based on an improvement in median
survival from 4.2 months to 5.7 months [6]. While this
was not a great improvement on the surface, one year sur-
vival increased from 2 to 18 %. Objective response rate
was very low (5.4 %) [6], but there was an improvement in
“clinical benefit response”, which reflects improvements in
disease-related symptoms. Importantly, there were no
good treatment alternatives. Gefitinib failed to demon-
strate a survival benefit in large trials on non-small cell
lung cancer [7, 8]. However, it was approved based on a
surrogate endpoint for clinical efficacy (response rate,
which was about 10 %). There is therefore some precedent
for approval of drugs based on benefits to the few and
based on response.
In a wide variety of circumstances, progression free
survival (PFS) is considered a good surrogate endpoint
[9–11]. In those conditions, clinical trials could be done
more economically and more quickly than trials where
overall survival is the primary endpoint. On the other
hand, the magnitude of treatment effects on PFS is
known to be higher than the effects on OS [12]. There-
fore, to some degree, as a community, we will need to
assign some value to achieving a progression free
interval.
Similarly, objective response (ie: reduction in tumor
size or attenuation; metabolic response) is associated
with a survival benefit in some studies [9, 13, 14]. In-
deed, if this were consistently the case, then early phase
trials could be designed using response as a primary
endpoint, which would dramatically accelerate drug de-
velopment and maybe even result in a more immediate
refinement of the target population for later stage trials.
There are several problems related to using response
as a clinical trial endpoint at this time. First, the rela-
tionship between response and survival is indirect: it is
not clear whether improved survivals are due to the re-
sponse per se or because of generally favorable tumor
biology. The role of biology is apparent in a surgical
series of colorectal liver metastases reported by Adam et
al., who observed that progression following neoadjuvant
chemotherapy (“bad biology”) was associated with poor
survivals after resection [15]. To emphasize this point,
Petrelli and coworkers have observed that, in metastatic
colorectal cancer, early tumor shrinkage is prognostic
but not sufficiently correlated with overall survival to act
as a surrogate [13]. Second, the significance of stable dis-
ease is not obvious. In some instances, stable disease
may represent a response; in others, it may represent in-
dolent tumor biology. Finally, response rate is a function
of methodology. Changes in tumor size, attenuation and
metabolic activity each reflect different drug effects;
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depending on the types of drugs used, response rates
vary depending on how they are measured. Therefore,
work is needed to refine methods of measuring response
and to establish the linkage of those refined measures to
clinical benefit.
Current methods of assessing response to therapy
Standard radiographic assessment
Presently, response to treatment is assessed radiographic-
ally – typically CT scan or MRI. The criteria for response
typically utilized for solid tumors treated with cytotoxic
agents are the RECIST criteria, based on changes in tumor
size [16, 17]. But the RECIST criteria are not well suited
for some situations. With some tumor types, including
esophagogastric cancers and biliary cancers, tumor extent
is difficult to assess radiographically. Cancers that have
spread to involve the peritoneum and the pleura are simi-
larly difficult to measure. In these circumstances, RECIST
criteria are not helpful for the assessment of a treatment
response. Some cytotoxic treatments are not associated
with reductions in tumor dimension. For example, hepato-
cellular carcinoma (HCC) submitted to locoregional treat-
ments such as transarterial chemoembolization and
radiofrequency ablation cause a high degree of tumor ne-
crosis, but there is often no accompanying reduction in
size [18]. RECIST criteria therefore underestimate thera-
peutic response rates.
RECIST criteria are similarly problematic for response
assessment following administration of targeted agents.
These agents are typically cytostatic, not cytotoxic, and
changes in the dimensions of the tumors are seen less
frequently [19, 20]. Therefore, by RECIST criteria, re-
sponse is underestimated. In instances of stable disease
(by RECIST criteria), it is also difficult to distinguish sta-
bility due to therapy versus stability due to indolent
tumor biology. To address this problem, Choi and co-
workers have described the use of CT to assess for
changes in attenuation [20]. Therapy-related reductions
in tumor attenuation, which may reflect inhibition of
angiogenesis or decreased tumor viability, are reportedly
associated with better progression-free survivals for
gastrointestinal stromal tumors (GIST), renal cell carcin-
oma (RCC) and HCC [19–21]. The Choi criteria are
therefore considered an important adjunct in response
evaluation following systemic treatment with molecular-
targeted agents.
Traditional response criteria may not be appropriate
for immune interventions, such as immune checkpoint
blockade, vaccines and adoptive therapy. As in the new
molecularly targeted agents, meaningful responses are
often associated with minimal or no reduction in tumor
size. Interestingly, in some individuals, progressive dis-
ease (as estimated by RECIST criteria) precedes a reduc-
tion in tumor dimension [22, 23]. This is not unlike the
situation following radiotherapy, where immediate post-
radiation changes may invoke an inflammatory response
accompanied by an increase in tumor dimension [24].
For this reason, it has been proposed that response after
immunotherapy be classified using specialized criteria.
Using these criteria, treatments are not discontinued im-
mediately with progressive disease unless progression is
sustained and confirmed [25].
Positron emission tomography (PET)
Functional imaging techniques have also been used to
assess treatment response. The most widely available
platform is [18 F] fluorodeoxyglucose (FDG) PET, which
reflects the metabolic activity of tumor. A reduction in
FDG avidity is observed with effective treatment. This
has been used effectively for monitoring response to
cytotoxic therapies as well as in targeted therapies [9].
Response can be categorized as soon as 4 weeks after
treatment [26]. Generally, metabolic response precedes
anatomic response, and metabolic response rate exceeds
response rate as determined by RECIST, yet metabolic
response still corresponds to improved survival [9].
While FDG-PET is most widely available, other radio-
tracers have some potential utility. 3′-deoxy-3′-18 F
fluorothymidine PET (FLT-PET) has interesting features
as a test for assessing response. FLT is taken up by rap-
idly proliferating cells, and reductions in maximum
tumor standardized uptake value (SUVmax) from base-
line have been reported within 7 days of starting gefi-
tinib in advanced lung adenocarcinoma patients [27].
Similarly, changes in FLT avidity have been reported as
early as a week after chemotherapy for breast cancer.
Importantly, FLT-PET can distinguish between a clinical
response and stable disease [28]. [18 F] fluorocholine
PET (FCH-PET) is based on increased choline uptake by
cancer cells because of increased phosphatidylcholine re-
quirements for cell membrane formation in highly pro-
liferative cells [29]. FCH-PET has similarly been used to
assess response in patients treated with enzalutamide for
metastatic castration-resistant prostate cancer (CRPC).
Early FCH-PET predicted progressive disease 3 months
before CT in 66 % of patients and was a significant pre-
dictor of progression free survival [30].
With the advent of PET, new criteria for response to
treatment have been developed, Positron Emission Tom-
ography Response Criteria in Solid Tumors (PERCIST)
[31]. The PERCIST criteria enable assessment of response
in tumors that may not change in size, but instead have a
functional decline, most typically a reduction in glycolysis
(as reflected by FDG avidity). Solid tumors invisible on
anatomical imaging can therefore be tracked. In a study of
patients receiving neoadjuvant chemotherapy for breast
cancer, FDG-PET and PERCIST criteria had greater sensi-
tivity, specificity and accuracy in predicting pathologic
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complete response (70.4, 95.7 and 90.8 %, respectively)
compared to RECIST utilizing MRI (45.5, 85.5 and 82.4 %
respectively) [32]. In a group of patients with non-small
cell lung cancer, PERCIST criteria, but not RECIST cri-
teria, predicted disease free survival [33]. More recently,
PERCIST metabolic response was able to predict overall
and progression free survival in patients with pancreatic
cancer liver metastases treated with 90Y-Yttrium micro-
spheres [34].
The use of PERCIST criteria to measure response has
some limitations. PET scans are not widely available and
repeated studies are expensive to execute. Moreover, in
many clinical facilities, PET scans are not implemented
in a manner that allows accurate calculation of PERCIST
criteria.
Other functional imaging modalities
Dynamic contrast enhanced ultrasonography (DCE-US)
is an alternative functional imaging technique that en-
ables quantitative assessment of tumor perfusion. It may
therefore play a role in assessing the efficacy of antian-
giogenic agents. DCE-US peak intensity was shown to
be a predictive tool in indicating early response efficacy
of sunitinib treated RCC patients 15 days after treatment
[35]. In HCC patients, DCE-US has been useful in iden-
tifying patients responding to sorafenib [36] and axitinib
[37]. Further clinical trials are in progress for evaluating
the roles of 3D dynamic contrast enhanced ultrasound
imaging contrast enhanced ultrasound, and shear wave
elastography.
Circulating tumor cells (CTCs)
CTCs can be detected by evaluation of tumor-specific
mRNA transcripts by reverse transcription polymerase
chain reaction. In general, this approach has been dif-
ficult to standardize because of the use of different
primers and assay conditions, making it difficult to
compare results between labs. Since the introduction
of assay systems to enumerate CTCs, a number of
studies have demonstrated that higher numbers of
CTCs are associated with a worse survival in a variety
of tumor types [38–41]. It therefore follows that a
treatment-induced reduction of CTCs would reflect
treatment efficacy. In metastatic breast cancer pa-
tients, a reduction in CTCs after 3–4 weeks of treat-
ment correlates with radiographic response [42]. Also
in metastatic breast cancer patients, a longer PFS is
seen in patients with <5 CTCs following initiation of
systemic therapy [43]. Overall survival is better in
metastatic breast cancer and castration resistant pros-
tate cancer (CRPC) patients where there is a
treatment-related reduction in the numbers of CTCs
[44, 45]. In patients with neuroendocrine tumors re-
ceiving various therapies, post-treatment reductions in
CTCs exceeding 50 % were associated with improved
survivals [46]. Monitoring CTCs during treatment
therefore represents an attractive strategy to monitor
treatment efficacy. The main problem with this ap-
proach is that accurate interpretation is difficult when
CTCs are undetectable or at low numbers. Therefore,
its implementation in all patients is hindered in that
population.
Circulating nucleic acids
Circulating tumor DNA (ctDNA) has been measured
to predict treatment outcome and assess response to
therapy [47–50]. In metastatic colorectal cancer pa-
tients treated with first line combinations of oxalipla-
tin or irinotecan (with or without biological therapy),
significant changes in ctDNA were seen as early as
3 days after initiating chemotherapy. The reductions
in ctDNA seen by 14–21 days correlated to response
(measured by CT using RECIST criteria). In patients
who had ≧10 fold reduction in ctDNA levels, 74 % had
a measurable response on CT; patients who had re-
ductions in ctDNA of this magnitude had a significant
improvement in PFS [51]. In metastatic melanoma pa-
tients treated with MAPK inhibitors, measurable re-
sponses were accompanied by reductions in ctDNA
after 4 – 8 weeks of therapy. Interestingly, in a group
of patients treated with immunotherapies (ipilimumab,
nivolumab or pembrolizumab), there was no signifi-
cant reduction in ctDNA. The authors also presented
data that suggested this strategy could be used for
early detection of acquired resistance [52].
Circulating microRNAs (miRs) have also been used
to measure disease burden. Plasma levels of miR-155,
197 and 182 significantly decreased with response to
chemotherapy in a small group of lung cancer pa-
tients [53]. Serum miR-155 levels were decreased in
breast cancer patients after surgery, but there were
no definitive data on the effects of chemotherapy on
miR-155 levels [54]. Following surgery in colorectal
cancer patients, circulating miR-17-3p and miR-92
levels drop [55]. In metastatic colorectal cancer pa-
tients treated with XELOX and bevacizumab, miR-126
levels decreased in responders and increased in non-
responders [56]. In 23 non-small cell lung cancer pa-
tients undergoing combined therapy, increasing levels
of miR-19b and decreasing levels of miR-125b were
associated with a therapeutic response [57].
Finally, long non-coding RNAs (lncRNA) have also been
used to assess response. In a small group of head and neck
cancer patients, following chemoradiotherapy, there was a
greater reduction in circulating lncRNA GAS5 levels asso-
ciated with complete response compared to PR/SD. Other
lncRNAs did not change with response [58].
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Circulating tumor markers
Tumor markers that are reliably elevated with disease
and that accurately reflect tumor burden may be used to
measure response. Unfortunately, those conditions are
infrequently met in most instances. Regardless, some
studies have shown the utility of using tumor markers to
assess response. In patients with HCC treated with so-
rafenib, survival was improved in individuals with a
>20 % decrease in alphafetoprotein [59]. In a cohort of
patients with colorectal liver metastases, a reduction of
>20 % in carcinoembryonic antigen (CEA) was highly
correlated with radiographic response [60]. Moreover, in
locally advanced or metastatic pancreatic endocrine car-
cinoma patients, chromogranin A (CgA) levels were
assessed at baseline and within 4 months of first cycle
fluorouracil, doxorubicin and streptozocin treatment. A
decrease of 30 % in the level of CgA from baseline was
found to be significantly correlated to RECIST defined
response (p = 0.04) [61]. Nucleosomes, neuron-specific
enolase (NSE), progastrin-releasing peptide (ProGRP),
cytokeratin-19 fragments (CYFRA 21–1) and CEA levels
were also investigated in a study of 128 small cell lung
cancer patients treated with various first line chemother-
apy regimens (eg. carboplatin, etoposide, and vincristine)
to assess response. Patients that responded to therapy
had a reduction in these biomarkers [62].
While tumor markers have been used to monitor the ef-
fects of systemic therapy for specific tumor types, their gen-
eral use in oncology practice is hampered by difficulties in
interpreting changes [63]. One exception is prostate specific
antigen (PSA), which is useful for monitoring treatment ef-
fects for prostate cancer. In 118 metastatic CRPC patients
treated with next generation androgen pathway inhibitors,
a PSA response (>50 % decrease in PSA levels from base-
line) at 28 days after treatment initiation was associated
with longer PFS and OS [64]. In a group of patients treated
with the oral androgen receptor antagonist MDV3100, the
model most predictive of prolonged PFS consisted of a pro-
longed decrease in monthly PSA levels at 12 weeks in con-
junction with a reduction in CTCs [65]. Therefore, PSA
measurements have found some use in monitoring treat-
ment response in prostate cancer. On the other hand, PSA
levels have limited usefulness in bone disease and when cy-
tostatic agents are administered [66–68], as well as when
dealing with certain subgroups of prostate cancers that do
not produce PSA [69].
Tissue-based biomarkers
Direct examination of tumor to evaluate the prolifera-
tion marker Ki67 before and after treatment has been
used to assess response [70–72]. Following hormonal
therapy for breast cancer, a lower Ki67 expression in
the surgical specimen was associated with improved
survivals [73]. Subsequently, post-treatment Ki67 levels
were used as a secondary endpoint in a trial comparing
three aromatase inhibitors [5]. While tissue-based bio-
markers are less convenient than blood-based bio-
markers, there may be some utility in the context of
tumors treated with neoadjuvant chemotherapy
followed by surgery.
Developing improved biomarkers of response
The potential benefits for a response biomarker are sub-
stantial (Table 1). However, the variable methods for asses-
sing response reflect the need for alternatives. Currently,
radiographic techniques are the gold standard for assessing
response. However, standard CT and MRI do not always
provide a clear signal of response, response may not appear
until a drug has been administered for a number of
months, and the clinical significance of stable disease is not
clear. Functional imaging is intriguing, but imaging
methods for assessing response are expensive and incon-
venient. Biopsy-based methods are challenging in many sit-
uations where tissue samples are hard to access, and they
are less attractive as whole because they are invasive.
Blood-based biomarkers are perhaps the most intriguing
methods under development because they are convenient
and much less expensive than radiographic tests.
The characteristics of the ideal response biomarker are
summarized in Table 2. To identify such a biomarker, we
propose a purposeful hypothesis-based approach to dis-
covery and validation. For example, one might devise a
biomarker that reflects the presence of tumor based on
one of the biological hallmarks of cancer (angiogenesis,
inflammation, disordered metabolism, etc.), and a thera-
peutic response may be manifested as a disappearance of
that signal. Alternatively, a biomarker that reflects cell
death or a reduction in cell proliferation could be
evaluated.
One experimental framework for discovery would in-
volve the serial collection of blood or urine before and
during systemic therapy, correlating changes in those
biofluids with radiographic response and progression
(Fig. 2). If radiographic response is used as a “gold
standard”, then a broad definition of response would be
required. For example, RECIST and Choi criteria or
PERCIST criteria could be used. In the case of stable dis-
ease, to distinguish treatment response from indolent
disease, changes associated with prolonged disease-free
survival could be identified.
As with any biomarker effort, there will need to be a
discovery phase as well as a validation phase. Sufficient
numbers of patients will be required to identify the bio-
marker in the three response categories (partial or
complete response; stable disease; and progressive dis-
ease). Following identification of the biomarker, a similar
approach could be utilized to validate the biomarker in a
larger, independent patient cohort.
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It is unlikely that a universal biomarker applicable to all
therapies (as described above) will emerge in early efforts.
Therefore, initial work should focus on response bio-
markers that are tumor- and drug-specific. To accomplish
this, sufficiently large cohorts receiving the same drugs or
drug combinations will be required to identify a response
biomarker. Typically, such cohorts would be encountered
in a phase III clinical trial. Clinical trials involve a rela-
tively homogeneous population; and outcomes such as re-
sponse and progression-free survival are well documented
following defined treatments. In addition, clinical trials
can be utilized to quickly do the discovery experiments,
followed by validation experiments. Therefore, clinical tri-
als should be built around this framework of serial sam-
pling before and during therapy.
Once a biomarker is discovered and validated, it
will be imperative to understand its kinetics. Does it
appear early or late after a response? How long after
response is it present? The optimal biomarker will be
detectable soon after treatment has been initiated,
disappearing with disease progression (or the emer-
gence of chemoresistance).
Ultimately, the biomarker must be reduced to prac-
tice. Assay design will have to ensure the reliable and
valid measurement of the biomarker. Health econo-
mists will help to inform decision makers by demon-
strating cost effectiveness of the biomarker compared
to standard of care, and also by estimating economic
advantages to other stakeholders. Any new biomarker
will require prospective assessment of its clinical util-
ity, which will drive uptake in the clinical community.
That is, clinicians and policy makers will need to ap-
preciate how the biomarker affects decision-making.
Table 1 Potential benefits of response biomarkers
Benefits to the Patient Effects on Clinical Practice Socioeconomic Benefits Benefits to Industry
Minimal exposure to potentially
toxic drugs that are
unbeneficial.
Can tailor therapy for patients by




companies and patients) will pay
much less for ineffective drugs.
Clinical trial design would be
revolutionized: a) Will provide a new
trial endpoint for phase I trials,
enabling identification of
appropriate doses and patient
populations with less harm to trial
participants. b) Phase II trials can be
performed more quickly, using the
biomarker as a surrogate marker for
benefit. c) Would greatly facilitate a
“go-no go” phase II-III adaptive
designs106.
Reduced cumulative toxicities
will improve quality of life.
The current practice is to administer
a drug until toxicities or disease
progression occur. A response
biomarker may inform on early
chemoresistance. This has the
following benefits: a) Inappropriate
dose escalations can be avoided. b)
Inappropriately prolonged treatments
can be avoided. c) Possibility of
rotating to a new potentially effective
drug regime before progression and
clinical deterioration occur.
Patients whose quality of life is
preserved and whose disease is
controlled with less toxicity will be
more likely to be able to resume
normal work activities.
Subpopulations that will benefit




administration of later lines of
therapy.
May enable dose titration: lowest
effective dose for an individual could
be administered.
Novel drug development will be less
expensive and more efficient. This
may translate to development of
more, less costly drugs.
It may become cost effective to
screen agents for use in rare cancers.
A response biomarker may
expand the therapeutic
armamentarium available for
patients: low cost trials of drugs
on individuals.
A serum biomarker of response
would enhance treatment of patients
with malignant conditions that are
difficult to gauge radiologically e.g.
peritoneal disease, bile duct cancer
and esophagogastric cancer.
There may be less need for
predictive biomarkers, which are
specific to each drug, and which
take years to develop and validate.
Table 2 Characteristics of the ideal response biomarker
Sufficiently sensitive to detect even minor responses that induce disease
stabilization.
Specific. Its absence accurately reflects chemoresistance.
Appears rapidly as a result of a response to therapy.
Agnostic to class of antineoplastic drugs.
Applicable to all tumor types.
Easy to measure, amenable to high-throughput testing.
Inexpensive.
Measurement is convenient to the patient and physician.
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Even more dramatic changes to clinical practice
would be expected if administration of the new test
(and the consequential changes in drug therapy) im-
proved clinical outcomes such as toxicities, quality of
life and survival. This will require a randomized con-
trolled trial comparing outcomes in patients treated
in the standard fashion (with radiographic and clinical
response assessment) and in patients whose response
is assessed using the new response biomarker.
Conclusion
There is a need to individualize cancer therapy, avoid-
ing expensive and toxic drugs that have no benefit.
Most of our efforts have been dedicated to identifying
predictive biomarkers. While there have been some
notable successes using that approach, there remain
significant challenges in the identification of predictive
biomarkers. The alternative approach is to identify
biomarkers that detect response, soon after therapy is
initiated, guiding the oncologist to continue or to
cease treatment with little exposure to toxic drugs.
Despite the significant advantages to that adaptive ap-
proach, so far, few efforts have been dedicated to de-
veloping response biomarkers. Future efforts should
be much more vigorous and purposeful. Reliable and
sensitive response biomarkers could potentially
revolutionize the way cancer drugs are administered
as well as how they are developed.
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